Expression of polo‐like kinase (PLK1) in thin melanomas: a novel marker of metastatic disease

Kneisel, Lucas; Strebhardt, Klaus; Bernd, August; Wolter, M.; Binder, Angelika; Kaufmann, Roland

doi:10.1034/j.1600-0560.2002.290605.x

Cited by 148 publications

(109 citation statements)

References 23 publications

Supporting

Mentioning

100

Contrasting

Unclassified

Order By: Relevance

“…This hypothesis matches well with observations that PLK1 expression is a survival parameter in oesophageal carcinoma (Tokumitsu et al, 1999), lung carcinoma (Wolf et al, 1997) and squamous cell carcinoma of head and neck (Knecht et al, 1999), and serves as a marker for metastatic disease in malignant melanoma (Kneisel et al, 2002).…”

Section: Discussionsupporting

confidence: 90%

“…Studies on the expression of PLK1 have been performed on carcinomas of lung (Wolf et al, 1997), head and neck (Knecht et al, 1999), oesophagus and stomach (Tokumitsu et al, 1999), skin (Kneisel et al, 2002), breast , brain (Dietzmann et al, 2001), endometrium and ovary (Takai et al, 2001a, b). All studies consistently reported an overexpression of PLK1 in the respective tumour tissue compared to the corresponding nontransformed tissue of origin.…”

mentioning

confidence: 99%

See 1 more Smart Citation

Polo-like kinase isoform expression is a prognostic factor in ovarian carcinoma

Weichert

Denkert

Schmidt³

et al. 2004

Br J Cancer

162

131

View full text Add to dashboard Cite

The Polo-like kinase (PLK) family comprises three serine/threonine kinases, functionally involved in signal transduction pathways essential for the accomplishment of mitosis in both normal and malignant cells. Moreover, certain PLKs have been functionally linked to cytoskeletal reorganisation. In this study, the expression of PLK1 and PLK3 was determined immunohistochemically in tissue specimen of normal ovaries (n ¼ 9), cystadenomas (n ¼ 17), borderline tumours (n ¼ 13) and ovarian carcinomas (n ¼ 77). PLK 1 and PLK3 expression was low in normal ovarian surface epithelium and borderline tumours, with moderately higher expression levels in cystadenomas. In ovarian carcinomas, 26% of cases were PLK1 positive and 50.6% of cases were PLK3 positive. A positive correlation of both PLK1 and PLK3 expression with indicators of mitotic frequency could be established. The overexpression of either isoenzyme had an impact on patient prognosis with shortened survival time for patients with tumours positive for PLK1 (P ¼ 0.02) and PLK3 (P ¼ 0.02), but only PLK1 expression remained a prognostic factor in multivariate survival analysis (P ¼ 0.03). The results of this study, if interpreted in the context of recently published functional data, suggest that inhibition of PLKs might represent an interesting new targeted approach for chemotherapy of epithelial ovarian cancer. Furthermore, this study suggests that PLK1 is a novel independent prognostic marker in ovarian carcinomas.

show abstract

Section: Discussionsupporting

confidence: 90%

mentioning

confidence: 99%

Polo-like kinase isoform expression is a prognostic factor in ovarian carcinoma

Weichert

Denkert

Schmidt³

et al. 2004

Br J Cancer

162

131

View full text Add to dashboard Cite

show abstract

“…Plk1 is overexpressed in a range of human tumors, including prostate tumors, ovarian carcinomas, hepatoblastomas and melanomas, and Plk1 overexpression was shown to coincide with bad prognosis (Kneisel et al, 2002;Weichert et al, 2004a, b;Yamada et al, 2004). Therefore, Plk1 is useful as a prognostic marker for outcome of disease.…”

Section: Plk1 and Cancermentioning

confidence: 99%

Getting in and out of mitosis with Polo-like kinase-1

2005

View full text Add to dashboard Cite

“…The human Plk1 was identified on basis of its high expression levels in rapidly proliferating cells (Holtrich et al, 1994). More recent data have suggested that elevated Plk1 expression in the primary tumor is associated with an unfavorable clinical outcome (Knecht et al, 1999;Kneisel et al, 2002), and experimental silencing of Plk1 has been shown to inhibit proliferative capacity of tumor cells (Spa¨nkuch-Schmitt et al, 2002;Elez et al, 2003). Efficient tumor cell cycle arrest at the G 2 /M boundary following IR exposure requires intact function of the tumor-suppressor protein BRCA1 (Scully and Livingston, 2000), and here we report that the mechanism may involve repression of PLK gene expression.…”

mentioning

confidence: 99%